Literature DB >> 17644747

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.

Alice Norton, Chris Fisher, Hui Liu, Qiang Wen, Gina Mundschau, Jose Luis Fuster, Henrik Hasle, Bernward Zeller, David K Webb, Aengus O'Marcaigh, April Sorrell, Joanne Hilden, Alan Gamis, John D Crispino, Paresh Vyas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17644747     DOI： 10.1182/blood-2007-03-080374

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

2.  Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.

Authors:  Hirotoshi Sakaguchi; Yusuke Okuno; Hideki Muramatsu; Kenichi Yoshida; Yuichi Shiraishi; Mariko Takahashi; Ayana Kon; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Hideki Makishima; Xinan Wang; Yinyan Xu; Sayoko Doisaki; Asahito Hama; Koji Nakanishi; Yoshiyuki Takahashi; Nao Yoshida; Jaroslaw P Maciejewski; Satoru Miyano; Seishi Ogawa; Seiji Kojima
Journal:  Nat Genet       Date:  2013-07-07       Impact factor: 38.330

3.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 4.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

Review 5.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

6.  Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.

Authors:  Sébastien Malinge; Tim Chlon; Louis C Doré; Rhett P Ketterling; Martin S Tallman; Elisabeth Paietta; Alan S Gamis; Jeffrey W Taub; Stella T Chou; Mitchell J Weiss; John D Crispino; Maria E Figueroa
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

Review 7.  JAK3: a two-faced player in hematological disorders.

Authors:  Melanie G Cornejo; Titus J Boggon; Thomas Mercher
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

8.  RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.

Authors:  David Koschut; Debleena Ray; Zhenhua Li; Emanuela Giarin; Jürgen Groet; Ivan Alić; Shirley Kow-Yin Kham; Wee Joo Chng; Hany Ariffin; David M Weinstock; Allen Eng-Juh Yeoh; Giuseppe Basso; Dean Nižetić
Journal:  Oncogene       Date:  2020-11-27       Impact factor: 9.867
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.